Drug intelligence / Profile preview

RP001

Development stage: Preclinical
Lead developer: RetiPharma
Modality: Peptides

Overview

RP001 is a neuroprotective peptide drug developed by RetiPharma, a spin-out from the University of Copenhagen. It is being prepared for a clinical proof-of-concept study in patients with retinal detachment and is intended for the treatment of degenerative eye disorders. The drug's intellectual property is based on extensive research on Neuropeptide Y (NPY) conducted at the University of Copenhagen, suggesting its mechanism of action involves NPY pathways to provide neuroprotection.

Targets

PYY receptor (Peptide YY receptor family)

Beyond the preview

Go deeper on RP001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RP001.

Explore the full profile